Targeted therapy in the treatment of solid tumors: Practice contradicts theory

被引：0
作者：
N. V. Zhukov
S. A. Tjulandin
机构：
[1] Ministry of Health Care and Social Security of the Russian Federation,Federal Research
[2] Russian Academy of Medical Sciences,Clinical Center for Pediatric Hematology, Oncology, and Immunology
来源：
Biochemistry (Moscow) | 2008年 / 73卷
关键词：
targeted therapy; breast cancer; colorectal cancer; VEGF; VEGFR; EGFR; HER-2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The basic principle of targeted therapy formulated about ten years ago consists in the design and application of drugs specifically directed against well-defined targets that are critical for tumor survival and not compromising for normal organs and tissues. The past decade has been marked by the appearance of an immense diversity of novel antitumor agents with claimed targeted action. Unfortunately, despite indisputable progress in clinical settings, some popular drugs against solid tumors (e.g. bevacizumab, trastuzumab, erlotinib, gefitinib) nominally assigned to targeted-action drugs, cannot actually be classified with this group being nonconforming to a priori stated goals of targeted therapy. The state-of-the-art and current problems in targeted therapy of solid tumors are reviewed.
引用
收藏
相关论文
共 652 条
  • [61] Robertson C.(2005)undefined J. Clin. Oncol. 23 5892-5042
  • [62] Cinieri S.(2007)undefined J. Clin. Oncol. 25 1545-2139
  • [63] de Braud F.(2005)undefined J. Clin. Oncol. 23 8081-1500
  • [64] Viale G.(2005)undefined N. Engl. J. Med. 353 133-13311
  • [65] Goldhirsch A.(2006)undefined J. Clin. Oncol. 24 5034-595
  • [66] Burstein H. J.(2004)undefined N. Engl. J. Med. 350 2129-452
  • [67] Spigel D.(2004)undefined Science 304 1497-124
  • [68] Kindsvogel K.(2004)undefined Proc. Natl. Acad. Sci. USA 101 13306-undefined
  • [69] Parker L. M.(2007)undefined J. Clin. Oncol. 25 587-undefined
  • [70] Bunnell C. A.(2007)undefined Cancer Met. Rev. 26 443-undefined
234567891011